Past Roles:• Advisor - Aurora Spectral Technologies LLC • Consultant - Univeristy of Wisonsin Milwaukee Partnerships for Innovation NSF Grant• Entrepreneur in Residence for TechStar, LLC – supported Milwaukee based high tech start ups including NovaScan (explosive detection systems and medical imaging), and NeuroGnostics (medical imaging)• Developed intellectual property strategy for Lucigen, a biotech start up• Developed revised business plan for GWC Technologies, Inc.• Member of Scientific Advisor Board of SpectruMedix Corporation and advisor on business strategy. Refocused corporate resources on promised markets in SNP detection, mutation screening, and proteomics• Consultant for GeneMachines, Inc. on development of plan for expansion into life sciences reagent business for DNA chips• Legal Consultant for Michael Best and Friedrich LLP of Madison, WI• Consultant for various other biotech start-ups.

Teaching courses in Entrepreneuring and Technology as part of a graduate degree program Master of Technology Entrepreneurship.

- CoFounder of company- Spin off of the Physics Department of the University of Wisconsin Milwaukee. - Raised $2M in angel money to launch company and first product- Developed and now marketing a new imaging system, OptiMiS, for use in studying proteins interaction in living cells in real time. - Offering system for sale to pharma research and university research labs.

• Co-founder of company• Based on technology from Dr. Phil Messersmith’s laboratory of Northwestern University• Target market: adhesive hydrogels as medical devices and biocoatings for prevention of bacterial infection• Developed new tissue adhesives that are both biocompatible and stronger than any competing products• Developed new thin film adhesive products that are best in class• Successfully financed the company through angel and venture capital investments totally just over $10M – lead investor Venture Investors LLC• Awarded over $2M in SBIR grants• Negotiated and implemented multi-year, multi-million development contract with major medical device company Developed key technical staff now totally 13 scientists and engineers, successfully recruited ‘business development ‘ CEO and CFO (Shaun Lonergan and David Sneider) to take the company through an acquisition process• Nerites sold to Kensey Nash for $20M in January 2010

Human Identity:• Identified new technologies to form basis of business (STRs, human DNA isolation and quantification systems).• Licensed technology and developed into products forming basis for a complete system to perform DNA typing of forensics samples from crime scene sample to finished analysis.• Developed worldwide sales and marketing effort for sale of products including new distribution outlets in Latin America and direct sales in Europe and Asia.• Increased sales from less than $1M to nearly $10M in five years and increased market position from number five to number two in the field.• Developed world class manufacturing operations to support rapid increase in sales.• Created financial model systems for managing expenses and forecasting sales.• Business became and remains profitable in 2000 after undergoing losses for the previous decade.Director Cell Biology• Targeted new product developments on high throughput system for drug discovery• Identified new technologies needed for high throughput screening for cell signaling assays including antibodies specific to activated kinases, 96 well plates for measuring kinase activity, and high throughput cell proliferation assays• Acquired technology through licenses or joint development efforts with outside companies for these new systems and developed technology in house into new product lines• Managed worldwide marketing efforts for these products.• Increased sales by three fold in less than four years to nearly $10M in sales.• Redesigned manufacturing operations and product line portfolio such that gross margins increased from 63% to 75%.

• Evaluated fluorescent technology available at company and developed plan for increasing revenues and profitability by developing applications using this technology, including nucleic acid gel staining, quantification, live cell assays and reporter assays. Several of these products became the largest selling products in the company.• Implementation of plan increased company sales annual growth from under 10% to over 30% in less than 18 months. Profitability increased from nearly zero to greater than 15% of annual sales.• Developed and implemented licensing program of company technology to diagnostics and life science research products companies. Generated in excess on $1M in revenues in second year of program.

Founder and Business Leader of Vysis Corporation, Amoco Technology Company, 1988-1993• Identified market opportunity for molecular cytogenetics in prenatal and cancer diagnostics• Identified and acquired exclusive licenses to key technologies for molecular cytogenetics, e.g., chromosome painting and automated karyotyping (image analysis).• Founded company in 1989 with first sales of AKS II, an automated karyotyping system.• Developed direct marketing and sales forces for both reagent and instrument product lines• Developed manufacturing effort and total quality systems from scratch including cGMP capability for both reagents and instruments.• Filed first 510K with FDA and received approval in six months• Vysis went public in 1998 and was sold to Abbott in 2001 for a price over $270,000,000.Director, Biosciences and Bioinformatics, Amoco Technology Company, 1985-1989• Identified marketing opportunity for bioinformatics systems in biotechnology• Key technical leader in team that acquired IntelliGenetics from IntelliGene• Developed R&D program for expanding bioinformatics base to include tools for function-structure predictions from DNA sequences and use of evolutionary sequences comparisons to predict protein structure and function• Technology and business sold to Oxford Biomedical in 1995Director, Biosciences Research and Development, Amoco Technology Company, 1983-1988• Identified and acquired technology needed for engineering yeast to produce very high levels of pharmaceutically important steroid molecules and precursors.• Developed yeast and chemical modification systems to product 25-hydroxy vitamin D at a cost significantly below present chemical synthetic means.• Business and technology sold to private investor in 1996.

Research Scientist, Plant Molecular Biology